Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effective dose study of injectable remimazolam besylate for sedation in post–cardiac surgery ICU patients on mechanical ventilation
ChiCTR2100051513Phase 4Not yet recruiting
- Sponsor
- Beijing An Zhen Hospital
- Start
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of remimazolam in None and Sedation requirement (5 arms), sponsored by Beijing An Zhen Hospital. Primary endpoint: Effective dose of remimazolam besylate for ICU sedation after cardiac surgery. Planned start Sep 2021; status: not yet recruiting.
02
Drugs
remimazolam
03
Conditions
Sedation requirement
Beyond the preview
Go deeper on ChiCTR2100051513.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100051513.